Clear Street analyst Kaveri Pohlman raised the firm’s price target on ArriVent Biopharma (AVBP) to $47 from $32 and keeps a Buy rating on the ...

The owner of an alpaca that is said to have tuberculosis and therefore is set to be culled, has claimed on ITV's This Morning that he (Geronimo) has not actually failed a validated test.

Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first ...

The Alpacca trial features a robust sample size of 480 patients with 1:1 randomization, which Clear Street believes strengthens the likelihood that firmonertinib will deliver positive, ...